Literature DB >> 20117004

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

Luca Mologni1, Roberta Rostagno, Stefania Brussolo, Phillip P Knowles, Svend Kjaer, Judith Murray-Rust, Enrico Rosso, Alfonso Zambon, Leonardo Scapozza, Neil Q McDonald, Vittorio Lucchini, Carlo Gambacorti-Passerini.   

Abstract

The synthesis, structure-activity relationships (SAR) and structural data of a series of indolin-2-one inhibitors of RET tyrosine kinase are described. These compounds were designed to explore the available space around the indolinone scaffold within RET active site. Several substitutions at different positions were tested and biochemical data were used to draw a molecular model of steric and electrostatic interactions, which can be applied to design more potent and selective RET inhibitors. The crystal structures of RET kinase domain in complex with three inhibitors were solved. All three compounds bound in the ATP pocket and formed two hydrogen bonds with the kinase hinge region. Crystallographic analysis confirmed predictions from molecular modelling and helped refine SAR results. These data provide important information for the development of indolinone inhibitors for the treatment of RET-driven cancers. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117004     DOI: 10.1016/j.bmc.2010.01.011

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

Authors:  Brendan Frett; Marialuisa Moccia; Francesca Carlomagno; Massimo Santoro; Hong-yu Li
Journal:  Eur J Med Chem       Date:  2014-09-08       Impact factor: 6.514

2.  Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.

Authors:  Iván Plaza-Menacho; Karin Barnouin; Kerry Goodman; Rubén J Martínez-Torres; Annabel Borg; Judith Murray-Rust; Stephane Mouilleron; Phillip Knowles; Neil Q McDonald
Journal:  Mol Cell       Date:  2014-02-20       Impact factor: 17.970

3.  The methionine-aromatic motif plays a unique role in stabilizing protein structure.

Authors:  Christopher C Valley; Alessandro Cembran; Jason D Perlmutter; Andrew K Lewis; Nicholas P Labello; Jiali Gao; Jonathan N Sachs
Journal:  J Biol Chem       Date:  2012-08-01       Impact factor: 5.157

4.  Regioselective synthesis of 2-(bromomethyl)-5-aryl-thiophene derivatives via palladium (0) catalyzed suzuki cross-coupling reactions: as antithrombotic and haemolytically active molecules.

Authors:  Komal Rizwan; Muhammad Zubair; Nasir Rasool; Shaukat Ali; Ameer Fawad Zahoor; Usman Ali Rana; Salah Ud-Din Khan; Muhammad Shahid; Muhammad Zia-Ul-Haq; Hawa Ze Jaafar
Journal:  Chem Cent J       Date:  2014-12-17       Impact factor: 4.215

5.  Dynamic, structural and thermodynamic basis of insulin-like growth factor 1 kinase allostery mediated by activation loop phosphorylation.

Authors:  Yaozong Li; Kwangho Nam
Journal:  Chem Sci       Date:  2017-03-20       Impact factor: 9.825

6.  Design, Synthesis and Preliminary Biological Evaluation of Novel Benzyl Sulfoxide 2-Indolinone Derivatives as Anticancer Agents.

Authors:  Lin Tang; Tao Peng; Gang Wang; Xiaoxue Wen; Yunbo Sun; Shouguo Zhang; Shuchen Liu; Lin Wang
Journal:  Molecules       Date:  2017-11-16       Impact factor: 4.411

7.  Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer.

Authors:  Hyo Jeong Lee; Pyeonghwa Jeong; Yeongyu Moon; Jungil Choi; Jeong Doo Heo; Yong-Chul Kim; Sun-Young Han
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06

8.  Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-substituted-hydrazinecarbothioamides.

Authors:  Subhas S Karki; Amol A Kulkarni; Sujeet Kumar; Suresh Kumar Veliyath; Erik De Clercq; Jan Balzarini
Journal:  Med Chem Res       Date:  2012-08-26       Impact factor: 1.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.